Post-Marketing Studies For All Products Endorsed By Drug Safety Expert
This article was originally published in The Pink Sheet Daily
Executive Summary
A mechanism is needed for post-marketing testing of all new drugs, safety expert Gross says during a Drug & Device Dialogue audio conference on the COX-2 advisory committee meeting. FDA “needs more tools” to protect public health, consumer rep Levin argues.
You may also be interested in...
Drug Safety To Be Topic Of Senate Health Hearings March 1 & 3
The Senate Health Committee will hold hearings on issues related to prescription drug safety March 1 and 3
COX-2 Cardio Risk Is Class Effect, But Varies By Drug And Dose, Cmte. Says
While a COX-2 class signal is likely, several committee members suggest data are not conclusive enough to make a "global" statement on the class. Voting FDA consultant Nissen recommends FDA explore whether COX-2 inhibition plays a role in hypertension, thereby contributing to an increased cardiovascular risk.
COX-2 Inhibitors Contraindicated For Heart Disease Patients In Europe
European Medicines Agency says COX-2 inhibitors should not be used in individuals with ischemic heart disease or stroke and recommends caution when prescribing the drugs for patients with risk factors for heart disease. Agency also adds a hypertension contraindication for Merck’s Arcoxia.